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Risk-adapted therapy has been the cornerstone of treatment for pediatric B precursor acute lymphoblastic
leukemia (B-ALL). Recently, age 13 years at diagnosis has been identiﬁed as a very high-risk feature for
chemotherapy treated pediatric patients with B-ALL. Whether age at time of transplantation is associated
with poor outcomes in adolescents and young adults (AYA) is unknown. We hypothesized that AYA receiving
allogeneic hematopoietic cell transplantation (allo-HCT) would have greater relapse and inferior survival
compared with children age <13 years. We reviewed the outcomes in 136 consecutive patients (age 0-30
years) with B-ALL who underwent myeloablative allo-HCT at our institution, including 79 children age <13
years (58%) and 57 AYA age 13-30 years (42%). Overall survival at 5 years was signiﬁcantly lower in the AYA
group (hazard ratio, 1.74; 95% conﬁdence interval [CI], 1.04-2.95; P ¼ .03). In addition, the AYA patients had
a greater risk of transplantation-related mortality at 1 year (hazard ratio, 2.23; 95% CI, 1.01-4.90; P ¼ .05), but
no difference in relapse (relative risk, 0.85; 95% CI, 0.41-1.76; P ¼ .66). Based on this analysis, AYA patients
undergoing allo-HCT for B-ALL have signiﬁcantly inferior survival and greater transplantation-related
mortality compared with children age <13 years, but no difference in relapse, suggesting that allo-HCT
may overcome relapse in AYA. Further improvements in peritransplantation care are needed to limit
complications in AYA patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION years, compared with 48.6% in patients age <10 years
Advances in the treatment of patients with pediatric
B-precursor acute lymphoblastic leukemia (B-ALL) have led
to dramatic improvements in both overall survival (OS) and
disease-free survival (DFS) [1]. Despite these advances,
however, cooperative group trials continue to identify
subgroups of B-ALL patients at greater risk for relapse after
chemotherapy [2,3]. These ﬁndings have led to intensiﬁca-
tion of therapy for patients deemed at high or very high risk
for relapse and, conversely, deescalation of therapy for those
at lower risk for relapse. Older age (10 years) at diagnosis
has long been associated with an increased risk of B-ALL
relapse [4,5], and recently the Children’s Oncology Group
(COG) has identiﬁed age 13 years at the time of diagnosis
as a very high-risk feature. In the COG’s CCG 1961 Study,
multimodal chemotherapy regimens in older patients
resulted in a 3-year postrelapse survival of 35.4% in
patients age 10-15 years and 14.7% in patients age >16edgments on page 141.
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12.08.020(P ¼ .001) [6].
Worse outcomes in chemotherapy-treated older children
and young adults with B-ALL have been reported by several
studies [7-9], leading to recognition that the adolescent and
young adult (AYA) patient group has unique needs and
challenges. Several possible explanations account for the
inferior outcomes seen in AYA patients, including poor
chemotherapy compliance [10,11] and a greater proportion
of patients with adverse risk factors, such as positive Phila-
delphia chromosome status (Phþ) or newly recognized high-
risk mutations/rearrangements in IKAROS [12], JAK [13], and/
or CRLF2 [14,15] genes. Whether these factors translate into
inferior transplantation outcomes is unknown. At present,
data are lacking on the impact of age on outcomes of allo-
geneic hematopoietic cell transplantation (allo-HCT) for
pediatric/AYA B-ALL. The AYA group has been deﬁned var-
iably, with ages spanning from 13-15 years up to 25-40 years
[16-19]. In the present study, we tested the hypothesis that
AYA patients (here deﬁned as age 13-30 years) would be at
higher risk for relapse after allo-HCT compared with patients
age <13 years.
PATIENTS AND METHODS
Study Design and Patient Characteristics
A total of 127 patients age 0-30 years diagnosed with B-ALL underwent
myeloablative allo-HCT at the University of Minnesota between 1995 andTransplantation.
Table 1
Patient Characteristics
Factor Total Age <13 Years Age 13-30 Years P Value
Number 127 74 53
Age, years, median (range) 9.97 (0.47-29.37) 5.74 (0.47-12.53) 17.70 (13.05-29.37)
Male sex, n (%) 80 46 (62) 34 (65)
Donor source, n (%) .96
BM 55 34 (46) 21 (40)
Related donor 32 17 (50) 15 (71) .08
Matched unrelated donor 19 15 (44) 4 (19)
Mismatched unrelated donor 4 2 (6) 2 (10)
Related PBSCs 7 2 (3) 5 (10)
UCB 65 38 (51) 27 (51)
Single 42 33 (87) 9 (33) <.01
Double 23 5 (13) 18 (67)
Remission status, n (%) .22
CR1 42 20 (27) 22 (42)
CR2 70 45 (60) 25 (47)
CR3 15 9 (12) 6 (11)
Recipient CMV status, n (%) .01
Negative 66 46 (62) 20 (38)
Positive 61 28 (38) 33 (62)
Phþ status, n (%) .33
Yes 19 13 (18) 6 (11)
No 108 61 (82) 47 (89)
MLL-R, n (%) .79
Yes 11 6 (8) 5 (9)
No 116 68 (92) 48 (91)
GVHD prophylaxis, n (%) .18
Cyclosporine 3 3 (4) 0
Cyclosporine/mycophenolate mofetil 44 21 (28) 23 (43)
Cyclosporine/methotrexate 56 32 (43) 24 (45)
Cyclosporine/Prednisone/antithymocyte globulin 19 15 (20) 4 (8)
Elutriation 5 3 (4) 2 (4)
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analysis. All patients and/or their parents or guardians provided a signed
consent to participate in an Institutional Review Boardeapproved trans-
plantation protocol, and outcomes were subsequently reviewed retrospec-
tively. Table 1 summarizes patient characteristics.
Seventy-four of the 127 patients (58%) were age <13 years and 53
patients (42%) were age 13-30 years at the time of allo-HCT. The median age
at allo-HCT was 5.74 years (range, 0.47-12.53 years) in the younger children
and 17.70 years (range, 13.05-29.37 years) in the AYA. There was a male
preponderance in both age groups. The median duration of follow-up was
5.96 years (range, 1.0-13.61 years) for patients age <13 years and 4.16 years
(range, 1.0-14.07 years) for the AYA patients. Before transplantation, 20
patients (27%) age <13 years were in ﬁrst complete remission (CR1), 45
(60%) were in second complete remission (CR2), and 9 (12%) were in third
complete remission (CR3); corresponding numbers for the AYA were 22
(42%), 25 (47%), and 6 (11%) (P ¼ .22). There was a trend toward a shorter
duration of CR1 with more early relapses (<36 months from diagnosis) in
the patients age <13 years compared with AYA patients (32 of 45 versus 13
of 25; P ¼ .06). For patients undergoing allo-HCT in CR2, there was no
difference in the time from relapse to transplantation between the 2 age
groups (P ¼ .19).
The time from initial diagnosis to transplantation was similar in the 2
groups, with a median of 963.5 days (range, 93-3711 days) for patients
age <13 years and 593 days (range, 80-4832 days) for the AYA patients
(P ¼ .43). Not surprisingly, the patients age <13 years were less likely to
have been exposed to cytomegalovirus (CMV) before transplantation
(38% versus 62%; P ¼ .01). Thirteen patients age <13 years (18%) had
a malignant clone with a Phþ rearrangement (ie, 9;22 translocation),
compared with 6 AYA patients (11%). In addition, 6 patients age <13 years
(8%) hadmixed lineage leukemia rearrangements (MLL-R), comparedwith 5
AYA patients (9%). Routine testing for other high-risk mutations, such as in
IKAROS, JAK, and CRLF2, was not performed in these 127 patients.Donor Selection and Conditioning Regimens
Stem cell sources included HLA-matched related donor bone marrow
(BM), matched unrelated donor peripheral blood stem cells (PBSCs),
matched unrelated donor or mismatched unrelated donor BM, and unre-
lated umbilical cord blood (UCB). Half of the patients <13 years of age
received unrelated UCB (n ¼ 38, 51%), while the other half received either
bone marrow (n¼ 34, 46%) or related PBSCs (n¼ 2, 3%) which was similar to
the AYA patients where half received related UCB (n ¼ 27, 51%) and the
remaining received either bone marrow (n ¼ 21, 40%) or PBSCs (n ¼ 5, 10%)(Table 1). More AYA patients than younger patients received 2 UBC units (P
.01). This difference is consistent with our institutional UBC selection
criteria, with older patients likely to weigh more and to require the higher
cell doses provided by 2 UCB units.
All patients received myeloablative conditioning consisting of cyclo-
phosphamide (120 mg/kg) with or without ﬂudarabine (75 mg/m2) with
total body irradiation (1320 cGy) in 96%, with busulfan/cyclophosphamide/
ﬂudarabine or etoposide/total body irradiation in the remaining 4%. Graft-
versus-host disease (GVHD) prophylaxis was primarily cyclosporine-based
in 122 patients (95%), with T cell depletion by elutriation in 5 patients.
Statistical Methods
Five outcomes were studied: OS, DFS, transplantation-related mortality
(TRM), GVHD, and relapse. The Kaplan-Meier method was used to estimate
OS and DFS, whereas cumulative incidencewas used to estimate TRM, GVHD
and relapse [20,21]. Cox multiple regression analysis was conducted to
determine OS and DFS, and competing-risk regression was used for TRM,
GVHD, and risk of relapse. Age (<13 years versus13 years) was the primary
factor considered for each endpoint in both univariate and multivariate
regression analyses. Other covariates used in the models included: number
of previous remissions at the time of transplantation, sex, CMV status, BM
versus UCB, HLA matching (in the case of double UCB transplantation,
matching of the engrafting cord was used), year of transplantation, and
presence of Phþ and MLL-R mutations. The backward method was used to
determine the ﬁnal model, with a P value .05 considered signiﬁcant in all
statistical tests. All statistical analyses was performed using SAS version 9.2
(SAS Institute, Cary, NC).
RESULTS
Neutrophil Engraftment and Survival
Engraftment by day 42 post-HCT (deﬁned as 3 consecu-
tive days with an absolute neutrophil count >500/mL)
occurred in 70 patients age <13 years (95%) and in 48 AYA
patients (91%). In univariate analysis, 5-year OS was signiﬁ-
cantly longer in the patients age <13 years compared with
the AYA patients (62% [95% conﬁdence interval (CI), 50%-70%]
versus 39% [95% CI, 26%-53%]; P ¼ .03) (Figure 1). This
ﬁnding was conﬁrmed in a multivariate analysis that
demonstrated a signiﬁcant reduction in OS for the AYA group
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Figure 1. Cumulative incidence of OS was 62% for patients age <13 years and
39% for the AYA patients.
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Figure 2. Cumulative incidence of TRM was 14% for patients age <13 years
and 28% for the AYA patients.
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contrast, 5-year DFS was not signiﬁcantly different between
the 2 patient groups in either univariate analysis (52%
[95% CI, 40%-63%] versus 40% [95% CI, 26%-53%]; P ¼ .18)
or multivariate analysis (relative risk [RR], 1.39; 95% CI,
0.85-2.25; P ¼ .18).TRM and GVHD
In multivariate analysis, the cumulative incidence of TRM
at 1 year was higher in the AYA patients comparedwith those
age <13 years (28% [95% CI, 16%-41%] versus 14% [95% CI, 6%-
21%]; P ¼ .04) (Figure 2). Moreover, in the multivariate
analysis, older age was associated with a 2-fold increase in
TRM (RR, 2.23; 95% CI, 1.01-4.90; P ¼ .05) (Table 2), and the
use of 6/6 HLA-matched UCB grafts was associated with
a 3-fold decrease in TRM compared with the use of 4/6 HLA-
matched UCB grafts (RR, 0.31; 95% CI, 0.13-0.78; P ¼ .01).
TRM did not differ in the 2 groups based on the number of
complete remissions before transplantation. There were no
signiﬁcant differences in TRM based on sex, graft source (BM
versus UCB), presence of GVHD, or CMV seropositivity before
transplantation. CMV-positive AYA patients had a nonsignif-
icantly greater TRM compared with CMV-positive patients
age<13 years (36% [95% CI, 20%-53%] versus 14% [95% CI, 2%-
27%]; P ¼ .07), but there was no signiﬁcant difference in TRM
between the 2 CMV-negative groups (15% [95% CI, 0-30%]
versus 13% [95% CI, 3%-23%]; P ¼ .82).
Comparing TRM in patients receiving the 2 primary graft
sources separately (BM and UCB) revealed signiﬁcantly
greater TRM at 1 year in AYA BM recipients compared with
younger BM recipients (41% [95% CI, 22%-60%] versus
13% [95% CI, 3%-24%]; P ¼ .01). There was no signiﬁcant
difference in TRM between AYA and younger UCB recipients
(15% [95% CI, 2%-29%] versus 14% [95% CI, 3%-25%]; P¼ .86). In
univariate or multivariate analyses, age (<13 years versusTable 2
Multivariate Analysis, AYA versus Age <13 Years
Factor RR (95% CI) P Value
OS 1.74 (1.04-2.95) .03
DFS 1.39 (0.85-2.25) .18
TRM 2.23 (1.01-4.90) .05
Relapse 0.80 (0.39-1.67) .56
Acute GVHD grade II-IV 1.38 (0.76-2.50) .28
Acute GVHD grade III-IV 0.71 (0.23-2.22) .56
Chronic GVHD 2.73 (0.93-7.96) .0713 years) was not a factor in the development of grade II-IV
acute GVHD (31% [95% CI, 21%-42%] versus 41% [95% CI,
27%-55%]; P ¼ .26), grade III-IV acute GVHD (11% [95% CI,
4%-18%] versus 8% [95% CI,1%-15%]; P¼ .59), or chronic GVHD
(7% [95% CI, 1%-12%] versus 15% [95% CI, 5%-25%]; P ¼ .06)
(Table 2).
An analysis of TRM based on the year of allo-HCT revealed
no difference between AYA patients and patients age <13
years who received HCT between 1990 and 2000 (27% [95%
CI, 5%-48%] versus 21% [95% CI, 5%-37%]; P ¼ .63). Patients
who underwent allo-HCT more recently (between 2000 and
2005) exhibited a signiﬁcant age-related difference in TRM
(10% [95% CI, 2%-18%] in younger patients versus 29% [5% CI,
14%-43%] in AYA patients; P ¼ .03), reﬂecting an overall
decline in TRM in the past several years for children age <13
years, but no change for AYA.
Causes of TRM in the AYA patients (n¼ 18) included organ
failure (n ¼ 5), infection (n ¼ 5), GVHD (n ¼ 4), graft failure
(n¼ 2), hemorrhage (n¼ 1), and veno-occlusive disease (n¼
1). In the patients age <13 years, causes of TRM included
GVHD (n ¼ 4), infection (n ¼ 4), organ failure (n ¼ 2), and
hemorrhage (n ¼ 1).
Relapse
There was no signiﬁcant difference in relapse at 1 year
between patients <13 years and AYA patients (24% [95% CI,
14%-34%] versus 19% [95% CI, 8%-30%]; P ¼ .72) (Figure 3). In
univariate analysis, the incidence of relapse at 1 year was
lower in patients who underwent allo-HCT in CR1 (n ¼ 42)
compared with those who did so in CR2 (n ¼ 70) or in CR3
(n ¼ 15) (10% [95% CI, 1%-18%] versus 30% [95% CI, 19%-41%]
versus 20% [95% CI, 0-40%]; both P ¼ .05). Keeping age in the
statistical model (age <13 years versus AYA), disease status
(CR1 versus CR2 or CR3) remained the most signiﬁcant risk
factor for relapse in multivariate analysis (RR, 5.72; 95% CI,
1.37-23.81; P ¼ .02). In addition, relapse was signiﬁcantly
lower in patients without MLL-R (RR, 0.18; 95% CI, 0.04-0.76;
P ¼ .02).
DISCUSSION
Although risk stratiﬁcation for chemotherapy in pediatric
B-ALL has identiﬁed patients at increased risk, the impact of
ageon transplantationoutcomes in childrenandyoung adults
with B-ALL undergoing allo-HCT is unknown. This analysis of
127 patients with B-ALL who underwent allo-HCT at a single
center identiﬁed a lower OS in AYA patients, likely due to
increased TRM. This is the ﬁrst report to identify an
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Figure 3. Cumulative incidence of relapse was 24% for patients age <13 years
and 19% for the AYA patients.
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inferior outcomes of allo-HCT in B-ALL, with a 2-fold greater
TRM in AYA patients. Moreover, the COG recently recognized
age 13 years as a very high risk factor associated with
a higher relapse rate and worse DFS after chemotherapy in
newly diagnosed patients with B-ALL (M. Devidas, personal
communication, February 2012). In contrast to this ﬁnding in
newly diagnosed patients, our ﬁndings on allo-HCT for pedi-
atric/AYAB-ALL showthat the relapse rate aftermyeloablative
conditioning is similar and independent of patient age.
Myeloablative allo-HCT for pediatric leukemia has been
associated with a 10%-30% risk of TRM, depending on
recipient factors (ie, remission status and performance
status), donor type, and conditioning regimen [22,23].
Advancements in donor selection, conditioning regimens,
infection monitoring/prophylaxis, and immunosuppression
have led to declining rates of TRM in pediatric patients
[23,24]. This increased risk of TRM in AYA patients is not
likely the direct result of more treatment, given the similar
remission status before transplantation in the 2 groups.
Furthermore, the 2 groups had similar numbers of patients
with early versus late relapse, and the time from diagnosis to
transplantation was relatively shorter in the AYA group.
Whether the increased TRM is also related to unique bio-
logical factors present in the AYA group or to factors not
identiﬁed in this analysis is not clear. Continuing investiga-
tion into methods of minimizing transplantation-related
toxicities is warranted.
Consistent with previous studies, disease status (CR1
versus CR2) at the time of HCT, irrespective of age, dramat-
ically increased the risk of future relapse [25-29]. We also
found a signiﬁcantly higher relapse rate in patients with
MLL-R. Abnormalities of 11q23 in B-ALL have been associated
with high risk of relapse in infants [30], but the prognostic
signiﬁcance of 11q23 identiﬁed in noninfant B-ALL remains
uncertain [31,32]. A large international study incorporating
11 cooperative groups and single institutions cited event-free
survival for noninfantMLL-R B-ALL ranging from 33% to 100%
based on a variety of clinical features [32]. In our cohort,
there was no signiﬁcant difference in the presence of either
Phþ or MLL-R between the 2 age groups, indicating that
neither cytogenetic abnormality can account for the inferior
outcomes seen in our AYA cohort.
In summary, in our cohort of patients with B-ALL, we
found signiﬁcantly inferior OS in the AYA compared
with children age <13 years, owing to greater TRM.
Our ﬁndings identify a new subgroup of B-ALL patients inthe AYA population in need of further improvements
in peritransplantation care. Our data support the allo-
transplantation graft-versus-leukemia effectemediated
relapse protection and provide a rationale for investiga-
tions to identify new pretransplantation risk factors that may
allocate older patients to allo-HCT in CR1 or CR2 rather than
CR3, when outcomes are signiﬁcantly worse [6,25].
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